- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases899
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathology1000+
- Pathologic Processes1000+
- Nervous System Diseases899
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- EGFR positive
- EGFR negative
- PD-L1 negative
- ER negative
- PR negative
- ALK negative
- KRAS positive
- BRAF positive
- BRCA1 positive
- BRCA2 positive
- CD20 positive
- ALK positive
- BRAF negative
- p16 positive
- HLA-A positive
- MET positive
- ROS1 negative
- MYC positive
- HLA positive
- ROS1 positive
- CD19 positive
- IDH negative
- MET negative
- PALB2 positive
- RET positive
- HLA negative
- HR positive
- IDH positive
- TP53 positive
- HLA-A negative
- PIK3CA positive
- p16 negative
- RB1 positive
- BRCA1 negative
- Bcl2 positive
- MSI-H positive
- RB1 negative
- BCL6 positive
- BCR-ABL1 positive
- BRCA positive
- BRCA2 negative
- CCND1 positive
- CD5 positive
- L858R positive
- NRAS positive
- RET negative
- ctDNA positive
- dMMR positive
- CFTR positive
- Ex19del positive
- HPV positive
- KRAS negative
- MGMT negative
- Philadelphia chromosome positive
- TP53 negative
- ATM positive
- HBsAg positive
- HPV negative
- MGMT positive
- NTRK positive
- RAS positive
- CD4 positive
- CLDN18.2 positive
- FGFR2 positive
- FLT3 positive
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- MSS positive
- NF1 positive
- NTRK negative
- PMS2 positive
- PTEN positive
- RAS negative
- TTR positive
- anti-dsDNA positive
- ABCA4 positive
- ANA positive
- CD19 negative
- CD20 negative
- CD22 positive
- CD3 positive
- DMD positive
- EBV positive
- FGFR3 positive
- FLT3 negative
- FMR1 positive
- HRAS positive
- HbSS positive
- KIT positive
- MDM2 positive
- MSI-H negative
- Philadelphia chromosome negative
- T790M positive
- TROP2 negative
- TROP2 positive
- ZnT8 positive
- pMMR positive
- t(11;14) positive
- 1p negative
- APP positive
- C5 positive
- CCNE1 positive
- CD23 positive
- CD8 positive
- CDK4 positive
- CHEK2 positive
- COL7A1 positive
- GPC3 positive
- HBV DNA negative
- HRD positive
- IA-2 positive
- IAA positive
- JAK2 positive
- MECP2 positive
- MMR negative
- MSI negative
- NTRK1 positive
- PSEN1 positive
- PSEN2 positive
- RAF positive
- RF positive
- RHO positive
- SMARCB1 negative
- SPINK5 positive
- dMMR negative
- p53 positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- 1p/19q co-deletion positive
- AGXT positive
- AKT negative
- ALPL positive
- AR positive
- Aβ1-42 positive
- BCL-2 positive
- BCL-6 positive
- BCMA positive
- BRIP1 positive
- CD1a positive
- CD2 positive
- CD22 negative
- CD30 negative
- CD30 positive
- CD34 positive
- CD38 positive
- CD4 count positive
- CD7 positive
- CD99 positive
- COL1A1 positive
- COL1A2 positive
- CRLF2 positive
- DLL3 positive
- Del(17p) negative
- Del(17p) positive
- EPCAM positive
- ER/PR positive
- EZH2 positive
- FGFR positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GLA positive
- GRHPR positive
- GRN positive
- HBB positive
- HBV DNA positive
- HBcAb positive
- HBsAg negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HTT positive
- HbE positive
- HbSC positive
- IGHV negative
- IGHV positive
- KMT2A positive
- L861Q positive
- MSI positive
- MSS negative
- MTAP positive
- MYC negative
- NF2 positive
- NPM1 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Activity Modification
- Acyclovir
- Adjuvant Chemoradiation after Surgical Resection
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Radiotherapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6099 trials
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests how well nivolumab works in treating patients with anal cancer after they've received other treatments. Nivolumab may help the body's immune system attack the cancer, and may prevent tumor cells from growing and spreading.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Get notified when new Non-Small Cell Lung Cancer trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying whether adding ibrutinib to chemotherapy before and after stem cell transplant helps the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying afatinib dimaleate with or without cetuximab to treat patients with non-small cell lung cancer that has EGFR mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new chemotherapy treatment for leukemia that includes an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 34 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a combination of drugs given with or without hormone therapy to see how well they work in treating patients with hormone receptor-positive, HER2-positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Approved for 20 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Get notified when new CLL trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different combinations of drugs to treat patients with newly diagnosed multiple myeloma.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50